Rapid Dose launches QuickStrip cannabis in Brazil

Executive Summary

• Rapid Dose Therapeutics Corp. has commercially launched its Entourage Phytolab co-branded QuickStrip medical cannabis oral thin film in Brazil, following regulatory approval from ANVISA for manufacturing and distribution.
• This launch positions Rapid Dose as one of the first companies to introduce an oral dissolvable strip medical cannabis product to the Brazilian healthcare market, leveraging a strategic partnership with U.S.-based distributor Nexxions.
• The product utilizes sublingual and buccal absorption routes, which were recently authorized by ANVISA, offering a precise, discreet, and rapid-onset alternative to traditional oils and capsules for treating conditions such as chronic pain, anxiety, and sleep disorders.

Key Details

• Product Launch: Commercial launch of QuickStrip, an oral thin film delivering controlled doses of active medical ingredients via sublingual or buccal absorption.
• Regulatory Approval: Approval granted by Brazil's National Health Regulatory Agency (ANVISA) for both manufacturing and distribution.
• Regulatory Context: ANVISA unanimously approved new rules on Jan. 28, 2026, complying with a Supreme Court of Justice decision. These rules expanded permitted routes of administration to include dermatological, sublingual, buccal, and inhalation methods (previously limited to nasal and oral).
• Partnerships:
  • Nexxions: U.S.-based distribution and marketing partner helping navigate Brazilian regulatory environments.
  • Entourage Phytolab: Co-branding partner; CEO Caio Abreu cited early trial data showing rapid relief (within minutes) and extended duration of benefit.
• Market Opportunity:
  • Brazil has a population of over 215 million.
  • ANVISA reported over 672,000 registered cannabis patients in Brazil, a 56% year-over-year increase.
  • The Brazilian medical cannabis market was valued at $856.53 million (USD) in 2025 and is forecast to reach $1.546 billion (USD) by 2034 (CAGR of 6.79%).
  • Approximately 50,000 doctors are actively prescribing cannabis-based medications in Brazil.
• Product Advantages:
  • Rapid onset compared to oils and edibles.
  • Discreet and portable form factor.
  • Precise dosing for treatment consistency.
  • Non-combustible, avoiding respiratory risks associated with inhalation.
• Access Channels: Patients can access cannabis via importing with ANVISA authorization, purchasing at pharmacies (49 products registered as of early 2026), or through patient associations allowed to cultivate (THC content up to 0.3% under new 2026 rules).

Notable Quotes

• Alan Mayo, Founder and President of Nexxions: "QuickStrip is a precise dosage, discrete solution provider for patients in Brazil... The simplicity, accuracy and reliability of QuickStrip make it a natural fit for patients and physicians seeking more effective, high-quality, non-combustible cannabis-based therapies."
• Caio Abreu, CEO of Entourage Phytolab: "We were impressed by how quickly patients experienced relief with QuickStrip -- often within minutes -- and the duration of benefit exceeded expectations... We see QuickStrip as the future of cannabis delivery, and we are proud that Entourage is the first to bring this innovation to Brazilian patients."
• Mark Upsdell, CEO of Rapid Dose Therapeutics: "The regulatory approval and launch of QuickStrip exporting medical cannabis to Brazil under the Entourage Phytolab brand represents a significant milestone in our global growth strategy. We're proud to introduce an innovative therapeutic option that meets a real and growing demand for better medical care across Latin America."